A review of pharmacovigilance

West Indian Medical Journal

Volumn 63, Issue 7, 2014, Pages 771-774

  Campbell, J E ^a   Gossell Williams, M ^a   Lee, M G ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Adverse reaction; Drug; Pharmacovigilance; Reporting

Indexed keywords

AZITHROMYCIN; DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE DRUG REACTION; ARTICLE; DEVELOPING COUNTRY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEALTH CARE PERSONNEL; HUMAN; MORBIDITY; MORTALITY; OFF LABEL DRUG USE; PRESCRIPTION; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 85034074438     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.7727/wimj.2013.251     Document Type: Article

References (52)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-59
2. World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions-why health professionals need to take action. Geneva: World Health Organization; 2002
3. World Health Organization. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: Uppsala Monitoring Centre, World Health Organization; 2000
4. Routledge P. 150 years of pharmacovigilance. Lancet 1998; 351: 1200-1
5. van Grootheest K. The dawn of pharmacovigilance. Intern J Pharm Med 2003; 17: 195-200
6. Rich ML. Fatal case of aplastic anaemia following chloramphenicol therapy. Ann Intern Med 1950; 33: 1459
7. Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969; 208: 2045-50
8. Randall T. Thalidomide's back in the news, but in more favorable circumstances. JAMA 1990; 263: 1467-8
9. Olsson S. The role of the WHO Programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998; 19: 1-10
10. World Health Organization. International drug monitoring: the role of national centres. Geneva: World Health Organization; 1972
11. Olsson S, Pal S, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and middle-income countries. Drug Saf 2010; 33: 689-703
12. Lazarou J, Pomeranz BH, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
13. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol [serial on the Internet] 2008; 1: 695-705. doi: 10.1586/17512433.1.5.695. Available from: http://www. medscape.com/viewarticle/583670
14. Aspinall MB, Whittle J, Aspinall SL, Maher RL Jr, Good CB. Improving adverse-drug-reaction reporting in ambulatory care clinics at a Veterans Affairs hospital. Amer J Health Syst Pharm 2002; 59: 841-5
15. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41: 192-9
16. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999; 15: 445-58
17. Benkirane R, ParienteA,Achour S, Ouammi L,AzzouziA, Soulaymani R. Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study. East Mediterr Health J 2009; 15: 1145-55
18. Jones J. Adverse drug reactions in the community health setting: approaches to recognizing, counselling, and reporting. Fam Community Health 1982; 5: 58-67
19. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol 2009; 9: 8. doi: 10.1186/1472-6904-9-8
20. CarmagoAL, Cardoso FerreiraMB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 2006; 62: 143-9
21. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007; 7: 8
22. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag 2005; 1: 181-8
23. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States.Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. Available from: http://www.cdc.org
24. Finklestein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28: w822-31. doi: 10.1377/hlthaff. 28.5.w822. Epub 2009 Jul 27
25. Lloyd-Jones D,Adams RJ, Brown TM, CarnethonM, Dai S, De Simone G et al. Executive summary: heart disease and stroke statistics-2010 update. Circulation 2010; 121: 948-54
26. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363-9
27. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. In: WHO Policy Perspectives on Medicines. Geneva: World Health Organization; 2004
28. Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med 2008; 358: 1427-9
29. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Inter Med 1996; 125: 605-13
30. Ray WA, Stein CM. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201
31. Pirmohamed M, Breckenridge A, Kitteringham NR, Park B. Adverse drug reactions. Br Med J 1998; 316: 1295-8
32. Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 2009; 68: 427-34
33. Egberts TCG. Signal detection: historical background. Drug Saf 2007; 30: 607-9
34. HaubenM, Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol 2005; 61: 479-80
35. Edwards IR, Biriell C. Harmonisation of pharmacovigilance. Drug Saf 1994; 10: 93-102
36. Stahl M, Edwards IR, Bowring G, KiuruA, Lindquist M. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of national pharmacovigilance centers. Drug Saf 2003; 26: 721-7
37. Hochberg AM, Reisinger SJ, Perason RK, O'Hara DJ, Hall K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J 2007; 41: 633-43
38. Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK et al. Post-approval drug safety surveillance. Annu Rev Public Health 2010; 31: 419-37. doi: 10.1146/annurev.publhealth. 012809.103649
39. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2007; 63: 148-56
40. Lazarou J, Pomeranz BH, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
41. Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004; 329: 15-9
42. Fletcher AP. Spontaneous adverse drug reaction reporting vs. event monitoring: a comparison. J Royal Soc Med 1991; 84: 341-4
43. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Martin Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54: 483-8
44. Pirmohamed M, Breckenridge A, Kitteringham NR, Park B. Adverse drug reactions. Br Med J 1998; 316: 1295-8
45. Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions? CMAJ 2006; 174: 191-2
46. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005; 172: 765-7
47. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of underreporting of adverse drug reactions: a systematic review. Drug Saf 2009; 2: 19-31
48. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J 1998; 317: 119-20
49. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-96
50. Pérez García M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiol Drug Saf 2011; 20: 1295-302
51. Gossell-Williams M, Adebayo S. The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica. Pharm Pract (Granada) 2008; 6: 187-90
52. Campbell JE. Assessment of the knowledge and attitude of pharmacovigilance and promoting the importance of adverse drug reaction reporting among physicians, pharmacists and dentists in Jamaica [PhD thesis]. Kingston: University of the West Indies; 2013